Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label datopotamab deruxtecan in previously treated advanced NSCLC
2020-005723-37Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Feb 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Gustave Roussy. Primary endpoint: Objective response rate. Started Feb 2021; status: active.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-005723-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005723-37.